Appendix 290 Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med. 2023 Feb;29(2):440-449. Doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Ibanez-Molero S, van Vliet A, Pozniak J, Hummelink K, Terry AM, Monkhorst K, Sanders J, Hofland I, Landeloos E, van Herck Y, Bechter O, Kuilman T, Zhong W, Marine JC, Wessels L, Peeper DS. SERPIN B9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. Oncoimmunology. 2022 Nov 29;11(1):2139074. Doi: 10.1080/2162402X.2022.2139074. eCollection 2022. Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, van den Heuvel MM, Broeks A, Haanen JBAG, Schumacher TN, Meijer GA, Smit EF, Monkhorst K#, Thommen DS#. PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Clin Cancer Res. 2022 Nov. 14;28(22):4893-4906. Doi: 10.1158/1078-0432.CCR-22-0992. #These authors jointly supervised this work. Trebeschi S, Bodalal Z, Boellaard TN, Tareco Bucho TM, Drago SG, Kurilova I, CalinVainak AM, Delli Pizzi A, Muller M, Hummelink K, Hartemink KJ, Nguyen-Kim TDL, Smit EF, Aerts HJWL, Beets-Tan RGH. Prognostic value of deep learning-mediated treatment monitoring in lung cancer patients receiving immunotherapy. Front Oncol. 2021 Mar 2;11:609054. Doi: 10.3389/fonc.2021.609054. eCollection 2021. Muller M*, Hummelink K*, Hurkmans DP, Niemeijer AN, Monkhorst K, Roder J, Oliveira C, Roder H, Aerts JG#, Smit EF#. A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors. Clin Cancer Res. 2020 Oct 1;26(19):5188-5197. Doi: 10.1158/10780432.CCR-20-0538. Epub 2020 Jul 6. *Co-first author. #These authors jointly supervised this work. Anagnostou V*, Niknafs N*, Marrone K, Bruhm DC, White JR, Naidoo J, Hummelink K, Monkhorst K, Lalezari F, Lanis M, Rosner S, Reuss JE, Smith KN, Adleff V, Rodgers K, Belcaid Z, Rhymee L, Levy B, Feliciano J, Hann CL, Ettinger DS, Georgiades C, Verde F, Illei P, Kay Li Q, Baras AS, Gabrielson E, Brock MV, Karchin R, Pardoll DM, Baylin SB, Brahmer JR, Scharph RB, Forde PM, Velculescu VE. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer. 2020 Jan 13;(1):99-111. Doi: 10.1038/s43018-019-0008-8. Epub 2020 Jan 13. *Co-first author.
RkJQdWJsaXNoZXIy MTk4NDMw